In the realm of personalized medicine and targeted cancer treatment, the understanding and identification of specific genetic mutations have become pivotal. DNA Labs UAE stands at the forefront of this revolutionary approach, offering comprehensive genomic profiling through the Oncomine Comprehensive Panel and the Oncomine Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) Test. These advanced diagnostic tools are designed to uncover the genetic alterations driving an individual’s cancer, enabling clinicians to tailor treatments more effectively.
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that screens for hundreds of cancer-related gene mutations, translocations, and fusion events across various tumor types. By providing a detailed genetic fingerprint of a tumor, this panel aids in identifying actionable mutations that can be targeted with specific therapies, thereby optimizing patient outcomes.
Complementing the Oncomine Comprehensive Panel, the Oncomine Tumor Mutation Burden and MSI Test offers additional insights into the tumor’s behavior. Tumor Mutation Burden (TMB) measures the number of mutations within a tumor’s genome, serving as a biomarker to predict response to immunotherapy. High TMB levels are associated with a better response to immune checkpoint inhibitors, making this information crucial for treatment planning. Microsatellite Instability (MSI) testing, on the other hand, identifies defects in the DNA mismatch repair system, which can lead to a higher mutation rate. Like TMB, MSI status can influence treatment decisions, particularly the use of certain immunotherapies.
Understanding the symptoms and conditions that warrant the use of the Oncomine Comprehensive Panel and the Oncomine TMB and MSI Test is essential for patients and healthcare providers. While these tests do not directly detect symptoms, they are particularly valuable for individuals diagnosed with advanced, metastatic, or refractory cancers where standard treatments have failed, or when the cancer’s origin is unknown. In such cases, a comprehensive genomic profiling can uncover specific genetic alterations that may be targeted by available therapies, offering hope for better outcomes.
The cost of the Oncomine Comprehensive Panel and the Oncomine Tumor Mutation Burden and MSI Test at DNA Labs UAE is set at 21,000 AED. This investment in personalized cancer care can significantly impact treatment decisions and, ultimately, patient survival rates. While the cost may seem substantial, the potential to identify the most effective treatment based on an individual’s unique tumor profile can be invaluable.
For more information about these cutting-edge tests and to understand how they can benefit you or your loved ones, visit DNA Labs UAE. Our team of experts is dedicated to providing the most advanced genetic testing services to support patients and healthcare providers in the fight against cancer.
In conclusion, the Oncomine Comprehensive Panel and the Oncomine Tumor Mutation Burden and MSI Test represent significant advancements in the field of oncology. By enabling a more precise understanding of the genetic underpinnings of an individual’s cancer, these tests pave the way for personalized treatment strategies that can lead to better patient outcomes. At DNA Labs UAE, we are proud to offer these state-of-the-art genomic profiling services, contributing to the global effort to combat cancer more effectively.
